Halozyme Therapeutics Inc.
NASDAQ:HALO 3:59:59 PM EDT
| Market Cap (Intraday) | 6.95B |
| Current PE | 53.85 |
| Forward PE | 55.29 |
| 2yr Forward PE | 30.25 |
| 10-Day MA | $49.64 |
| 50-Day MA | $46.30 |
| 200-Day MA | $33.45 |
Halozyme Therapeutics, Inc. Stock, NASDAQ:HALO
11388 Sorrento Valley Road, San Diego, California 92121
United States of America
Phone: +1.858.794.8889
Number of Employees: 132
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.